{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T07:40:01Z","timestamp":1678606801516},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,3,17]],"date-time":"2007-03-17T00:00:00Z","timestamp":1174089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2007,3,17]],"date-time":"2007-03-17T00:00:00Z","timestamp":1174089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1007\/s10637-007-9043-x","type":"journal-article","created":{"date-parts":[[2007,3,16]],"date-time":"2007-03-16T14:13:45Z","timestamp":1174054425000},"page":"463-470","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Docetaxel\u2013ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines"],"prefix":"10.1007","volume":"25","author":[{"given":"Christos","family":"Kosmas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Tsavaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Malamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Tsakonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argyris","family":"Gassiamis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristidis","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Karabelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,3,17]]},"reference":[{"key":"9043_CR1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.1999.17.4.1127","volume":"17","author":"E Salminen","year":"1999","unstructured":"Salminen E, Bergman M, Huhtala S, Ekholm E (1999) Docetaxel: standard recommended dose of 100\u00a0mg\/m2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy\u2014a phase II single-center study. J Clin Oncol 17:1127\u20131131","journal-title":"J Clin Oncol"},{"key":"9043_CR2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","volume":"17","author":"JM Nabholtz","year":"1999","unstructured":"Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M, for the 304 Study Group (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17:1413\u20131424","journal-title":"J Clin Oncol"},{"key":"9043_CR3","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/S0959-8049(99)00122-7","volume":"35","author":"J Sjostrom","year":"1999","unstructured":"Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with cross over on progression by the Scandinavian Breast Group. Eur J Cancer 35:1194\u20131201","journal-title":"Eur J Cancer"},{"issue":"Suppl 4","key":"9043_CR4","first-page":"12","volume":"9","author":"A Monnier","year":"1998","unstructured":"Monnier A, Bonneterre J, Roche H, Fargeot P, Namer M, Guastalla JP, Rios M, Serin D, Culine S, Tubiana M (1998) Phase III study: Taxotere (TXT) versus 5-Fluorouracil\u2009+\u2009navelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as 2nd line chemotherapy. Ann Oncol 9(Suppl 4):12 (abstr 58O)","journal-title":"Ann Oncol"},{"key":"9043_CR5","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","volume":"17","author":"S Chan","year":"1999","unstructured":"Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 17:2341\u20132354","journal-title":"J Clin Oncol"},{"key":"9043_CR6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1200\/JCO.2000.18.4.724","volume":"18","author":"R Paridaens","year":"2000","unstructured":"Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18:724\u2013733","journal-title":"J Clin Oncol"},{"key":"9043_CR7","first-page":"1a","volume":"16","author":"GW Sledge Jr","year":"1997","unstructured":"Sledge GW Jr, Neuberg D, Ingle J, Martino S, Wood W (1997) Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin\u2009+\u2009paclitaxel (A\u2009+\u2009T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Proc Am Soc Clin Oncol 16:1a (abstr 2)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"9043_CR8","first-page":"861","volume":"58","author":"DI Ahmann","year":"1974","unstructured":"Ahmann DI, Bisel HF, Hahn RG (1974) Phase II clinical trial of isophosphamide (NSC-109724) in patients with advanced breast cancer. Cancer Chemother Rep 58:861\u2013865","journal-title":"Cancer Chemother Rep"},{"key":"9043_CR9","first-page":"185","volume":"1","author":"JD Bitran","year":"1995","unstructured":"Bitran JD, Samuels BL, Marsik S, Gambino A, White L (1995) A phase I study of ifosfamide and doxorubicin with recombinant human granulocyte colony-stimulating factor in stage IV breast cancer. Clin Cancer Res 1:185\u2013188","journal-title":"Clin Cancer Res"},{"key":"9043_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<561::AID-CNCR19>3.0.CO;2-#","volume":"82","author":"CA Bunnell","year":"1998","unstructured":"Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E, Shulman LN (1998) A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer 82:561\u2013566","journal-title":"Cancer"},{"key":"9043_CR11","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.1996.14.11.2993","volume":"11","author":"BA Leone","year":"1996","unstructured":"Leone BA, Vallejo CT, Romero AO, Perez JE, Cuevas MA, Lacava JA, Sabatini CL, Dominguez ME, Rodriguez R, Barbieri MR, Ortiz EH, Salvadori MA, Acuna LA, Acuna JM, Langhi MJ, Amato S, Machiavelli MR (1996) Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 11:2993\u20132999","journal-title":"J Clin Oncol"},{"key":"9043_CR12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjc.1998.24","volume":"77","author":"LC Pronk","year":"1998","unstructured":"Pronk LC, Schrijvers D, Schellens JH, de Bruijn EA, Planting AS, Locci-Tonelli D, Groult V, Verweij J, van Oosterom AT (1998) Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. Br J Cancer 77:153\u2013158","journal-title":"Br J Cancer"},{"key":"9043_CR13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/sj.bjc.6600887","volume":"88","author":"C Kosmas","year":"2003","unstructured":"Kosmas C, Tsavaris N, Malamos N, Stavroyianni N, Gregoriou A, Rokana S, Polyzos A (2003) Phase I\u2013II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. Br J Cancer 88:1168\u20131174","journal-title":"Br J Cancer"},{"key":"9043_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207\u2013214","journal-title":"Cancer"},{"key":"9043_CR15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-105-3-429","volume":"105","author":"R Simon","year":"1986","unstructured":"Simon R (1986) Confidence interval for reporting results of clinical trials. Ann Intern Med 105:429\u2013435","journal-title":"Ann Intern Med"},{"key":"9043_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2307\/2281868","volume":"53","author":"EL Kaplan","year":"1959","unstructured":"Kaplan EL, Meier P (1959) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"9043_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"issue":"Suppl. 6","key":"9043_CR18","first-page":"90","volume":"22","author":"E Reed","year":"1995","unstructured":"Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M (1995) Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 22(Suppl. 6):90\u201396","journal-title":"Semin Oncol"},{"key":"9043_CR19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/bjc.1996.341","volume":"74","author":"U Klaassen","year":"1996","unstructured":"Klaassen U, Harstrick A, Schleucher N, Vanhoefer U, Schroder J, Wilke H, Seeber S (1996) Activity and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines. Br J Cancer 74:224\u2013228","journal-title":"Br J Cancer"},{"key":"9043_CR20","first-page":"25","volume":"6","author":"JE Liebmann","year":"1994","unstructured":"Liebmann JE, Fisher J, Teague D (1994) Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6:25\u201331","journal-title":"Oncol Res"},{"issue":"Suppl. 6","key":"9043_CR21","first-page":"16","volume":"22","author":"CM Kearns","year":"1995","unstructured":"Kearns CM, Gianni L, Egorin MJ (1995) Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22(Suppl. 6):16\u201323","journal-title":"Semin Oncol"},{"key":"9043_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1054\/bjoc.1999.0919","volume":"82","author":"C Kosmas","year":"2000","unstructured":"Kosmas C, Tsavaris N, Polyzos A, Malamos NA, Katsikas M, Antonopoulos MJ (2000) Phase I study of dose escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. Br J Cancer 82:300\u2013307","journal-title":"Br J Cancer"},{"key":"9043_CR23","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/1097-0142(20000815)89:4<774::AID-CNCR9>3.0.CO;2-5","volume":"89","author":"C Kosmas","year":"2000","unstructured":"Kosmas C, Tsavaris N, Polyzos A, Kaolofonos HP, Malamos NA, Sepsas E, Malamos NA, Vadiaka M, Dosios T, Antonopoulos MJ (2000) A phase II study of paclitaxel\u2013ifosfamide\u2013cisplatin (PIC) combination in advanced non-small cell lung cancer. Cancer 89:774\u2013782","journal-title":"Cancer"},{"key":"9043_CR24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.2001.19.1.119","volume":"19","author":"C Kosmas","year":"2001","unstructured":"Kosmas C, Tsavaris NB, Malamos NA, Vadiaka M, Koufos C (2001) A phase II study of paclitaxel\u2013ifosfamide\u2013cisplatin (PIC) as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol 19:119\u2013126","journal-title":"J Clin Oncol"},{"key":"9043_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/ijc.10162","volume":"98","author":"C Kosmas","year":"2002","unstructured":"Kosmas C, Tsavaris N, Onyenadum A, Vadiaka M, Stavroyianni N, Sepsas E, Dimitropoulos D, Rokana S, Kalofonos HP (2002) A phase I\u2013II study of docetaxel\u2013ifosfamide\u2013cisplatin (DIP) combination chemotherapy regimen in advanced non-small cell lung cancer. Int J Cancer 98:141\u2013147","journal-title":"Int J Cancer"},{"key":"9043_CR26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1200\/JCO.1996.14.3.783","volume":"14","author":"MJ Kennedy","year":"1996","unstructured":"Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Sartorius S, Chen TL, Bowling K, Rowinsky EK (1996) Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14:783\u2013791","journal-title":"J Clin Oncol"},{"key":"9043_CR27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1200\/JCO.1996.14.1.95","volume":"14","author":"AW Tolcher","year":"1996","unstructured":"Tolcher AW, Cowan KH, Noone MH, Denicoff AM, Kohler DR, Goldspiel BR, Barnes CS, McCabe M, Gossard MR, Zujewski J, O\u2019Shaughnessy JA (1996) Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 14:95\u2013102","journal-title":"J Clin Oncol"},{"key":"9043_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1023\/A:1008211629858","volume":"8","author":"O Pagani","year":"1997","unstructured":"Pagani O, Sessa C, Martinelli G, Cerny T, de Jong J, Goldhirsch A, Zimatore M, Cavalli F (1997) Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Ann Oncol 8:655\u2013661","journal-title":"Ann Oncol"},{"key":"9043_CR29","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/00000421-200008000-00010","volume":"23","author":"D Schrijvers","year":"2000","unstructured":"Schrijvers D, Pronk L, Highley M, Bruno R, Locci-Tonelli D, De Bruijn E, Van Oosterom AT, Verweij J (2000) Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. Am J Clin Oncol 23:358\u2013363","journal-title":"Am J Clin Oncol"},{"key":"9043_CR30","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1023\/A:1008386000547","volume":"10","author":"T Cerny","year":"1999","unstructured":"Cerny T, Leyvraz S, von Briel T, Kupfer A, Schaad R, Schmitz SF, Honegger P, Sessa C, Brunner J, Boddy AV (1999) Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 10:1087\u20131094","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"9043_CR31","first-page":"36","volume":"11","author":"V Lorusso","year":"2000","unstructured":"Lorusso V, Crucitta E, Sambiasi D, Attolico M, De Lena M (2000) Docetaxel plus ifosfamide in advanced breast cancer refractory to anthracyclines: a phase II study. Ann Oncol 11(Suppl 4):36 (abstract 154)","journal-title":"Ann Oncol"},{"key":"9043_CR32","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","volume":"13","author":"PM Ravdin","year":"1995","unstructured":"Ravdin PM, Burris HA 3rd, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE (1995) Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879\u20132885","journal-title":"J Clin Oncol"},{"key":"9043_CR33","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1200\/JCO.1995.13.12.2886","volume":"13","author":"V Valero","year":"1995","unstructured":"Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN (1995) Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886\u20132894","journal-title":"J Clin Oncol"},{"key":"9043_CR34","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","volume":"20","author":"J O\u2019Shaughnessy","year":"2002","unstructured":"O\u2019Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J-P, Cervantes G, Fumoleau P, Jones S, Lui W-Y, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812\u20132823","journal-title":"J Clin Oncol"},{"key":"9043_CR35","first-page":"16S","volume":"23","author":"S Chan","year":"2005","unstructured":"Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Lluch A, Schneeweiss A, Llombart A, Carrasco E, Fumoleau P (2005) Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. J Clin Oncol 23:16S, 581 (abstr)","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-007-9043-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-007-9043-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-007-9043-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-007-9043-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:24:37Z","timestamp":1678559077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-007-9043-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,17]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["9043"],"URL":"https:\/\/doi.org\/10.1007\/s10637-007-9043-x","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,17]]},"assertion":[{"value":"9 December 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}